

ETIC Completes Support for Kishimoto Clinical Laboratory and Related Company

October 19th, 2011

Enterprise Turnaround Initiative Corporation of Japan

The Enterprise Turnaround Initiative Corporation of Japan (“ETIC”), following its decision on December 9th, 2010 to provide support to Kishimoto Clinical Laboratory and Dotou Clinical Laboratory, Inc. (hereafter collectively “Kishimoto Laboratories”) under Article 25, Clause 4 of the Enterprise Turnaround Initiative Corporation of Japan Act (Act 63, of 2009, hereafter “the ETIC Act”), has been provided support to Kishimoto Laboratories concomitant with its decision. In accordance with the revitalization plan and with the support of ETIC, on April 1st, 2011, Kishimoto Laboratories transferred their continuing operations to a new company after the absorption and separation with a wholly owned subsidiary of BML Inc. (hereafter the “Sponsor”). The continuing operations of the company are now part of the Sponsor group and today, following the completion of all the operational transfer procedures, ETIC has completed its support for Kishimoto Laboratories.

Note: Following the company separation, on June 27th, 2011, the former Kishimoto Laboratory (current trade name “Shinkawa Kanzai K.K.”) received a decision from the Sapporo District Court for the commencement of special liquidation proceedings, and is currently in the midst of these proceedings.

1. Name of companies concerned

Kishimoto Clinical Laboratory, Inc. and Doutou Clinical Laboratory, Inc.

2. Amount of financial support, etc.

ETIC’s support for Kishimoto Laboratories under Article 31, Clause 1 of the ETIC Act included a decision not to purchase debt of Kishimoto Laboratories, and, concomitant with this decision, no debt was purchased.

3. Outline of support provided by ETIC

ETIC’s role in supporting Kishimoto Laboratories was to facilitate coordinations among the financial institutions, the sponsors, Kishimoto Laboratories and the other stakeholders.

ENDS